Li et al. have identified that re-expression of miR-34a in oxaliplatin-resistant CRC cells can increase their mRNA stability and restore sensitivity to oxaliplatin by targeting ornithine decarboxylase antizyme 2 (OAZ2) [162]. The gene discussed is OAZ2; the disease is colorectal carcinoma.